Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management. Several complement inhibitors have been approved since eculizumab, including ravulizumab, a ...
The FDA approved iptacopan for treatment of adults with paroxysmal nocturnal hemoglobinuria. Iptacopan (Fabhalta, Novartis) is an oral selective complement factor B inhibitor designed to be given as ...
AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...
The U.S. FDA has approved Novartis AG’s Fabhalta (iptacopan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria, a rare blood disease that impairs blood cell production.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback